Company Overview

Janux Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on engineered T cell engager therapeutics designed to selectively activate immune responses against tumor cells while reducing systemic toxicity. Janux’s core platform technologies include its proprietary Tumor Activated T Cell Engager (TRACTr) platform and Tumor Activated Immunomodulator (TRACIr) platform, both intended to improve the therapeutic index of immuno-oncology agents by enabling activation primarily within the tumor microenvironment.

The company’s principal revenue drivers currently consist of collaboration and licensing agreements, as Janux remains in the clinical development stage and does not yet market approved commercial products. Janux has focused heavily on prostate cancer and other solid tumors, including programs targeting PSMA and EGFR. The company was founded in 2017 and is headquartered in San Diego, California. Since its formation, Janux has evolved from a platform-focused research organization into a clinical-stage oncology company advancing multiple internally developed therapeutic candidates through human trials.

Business Operations

Janux primarily operates through integrated research and development functions centered on its proprietary TRACTr and TRACIr technology platforms. The company generates revenue principally from research collaborations, milestone payments, and licensing arrangements rather than product sales. Its lead clinical programs include JANX007, a PSMA-targeted T cell engager for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeted program for solid tumors. The company’s therapeutic design strategy seeks to improve tolerability by masking T cell engager activity until localized activation occurs within tumor tissue.

Operations are concentrated in the United States, though the company’s development activities and future commercialization opportunities have international relevance through potential partnerships and global oncology markets. Janux has entered into strategic collaborations with external biotechnology and pharmaceutical organizations to support discovery and development efforts. The company maintains internal control over its core platform technologies, intellectual property portfolio, and preclinical research capabilities while relying on contract research organizations and manufacturing partners for portions of clinical and production activities common in the biotechnology sector.

Strategic Position & Investments

Janux’s strategic direction centers on expanding its portfolio of tumor-activated immunotherapies for solid tumors while differentiating itself from earlier-generation T cell engager developers through improved safety and tumor selectivity. The company has prioritized advancing clinical-stage oncology candidates while continuing to invest in platform optimization and additional discovery programs. Management has emphasized the potential for broader application of its masking and activation technologies across multiple tumor-associated antigens and immune pathways.

The company has also pursued growth through external collaborations and capital market financing to support clinical development. Janux has invested substantially in expanding its pipeline targeting difficult-to-treat cancers and enhancing translational research capabilities. While Janux does not currently maintain a large portfolio of operating subsidiaries, its strategic value is closely tied to its proprietary immunotherapy platforms, intellectual property estate, and clinical oncology pipeline. Data from ongoing trials and regulatory interactions are expected to play a central role in determining future partnership opportunities and commercialization pathways.

Geographic Footprint

Janux is headquartered in San Diego, California, a major biotechnology hub in the United States, and conducts most of its operations domestically. Its clinical development programs are primarily managed through U.S.-based facilities and research partnerships, though clinical trial activities may include international sites depending on study design and enrollment requirements. The company participates in the broader global oncology therapeutics market through scientific collaborations, investor engagement, and potential future licensing opportunities.

The company’s operational influence is currently strongest in North America, particularly within the U.S. biotechnology and clinical research ecosystem. However, the diseases targeted by Janux’s therapies, including advanced solid tumors and prostate cancer, represent significant global oncology markets. As clinical development progresses, the company may expand its international presence through multinational trials, regulatory submissions, or commercialization partnerships in regions such as Europe and Asia-Pacific.

Leadership & Governance

Janux was co-founded by David A. Campbell, Ph.D., who has played a central role in shaping the company’s scientific and strategic direction. Leadership has consistently emphasized innovation in tumor-selective immunotherapy and disciplined clinical advancement of oncology assets. The company operates under a governance structure typical of publicly traded biotechnology firms, with executive leadership overseeing clinical development, scientific research, finance, and corporate strategy.

Key executives include:

• David A. Campbell, Ph.D. – President and Chief Executive Officer
• Wayne Godfrey – Chief Financial Officer
• Andrew Hollman, M.D. – Chief Medical Officer
• Mark Lee, Ph.D. – Chief Scientific Officer
• Miriam Kim, J.D. – General Counsel and Corporate Secretary

Leadership strategy has focused on advancing differentiated immuno-oncology technologies, maintaining financial flexibility for clinical development, and positioning the company for long-term value creation through pipeline expansion and potential strategic partnerships.